This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYTRUDA® (pembrolizumab) in adjuvant renal cell carcinoma (RCC)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.1

Learn more about adjuvant RCC

Learn about KEYNOTE-564 to better understand KEYTRUDA vs. placebo in the adjuvant treatment of adults with RCC.

KEYNOTE-564 is a phase 3 landmark, multicentre, randomised, double-blind, placebo-controlled clinical study in 994 patients with intermediate-high or high risk of recurrence, or M1 NED.

Identify which of your patients with RCC will be eligible for KEYTRUDA in the adjuvant setting, post nephrectomy.

Reference

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-RCC-00373 | Date of Preparation: April 2022